It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms. Here we perform a comprehensive analysis of the plasma proteome of more than 1400 proteins in children with SARS-CoV-2. We hypothesize that the proteome would reflect heterogeneity in hyperinflammation and vascular injury, and further identify pathogenic mediators of disease. We show that protein signatures demonstrate overlap between MIS-C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic microangiopathy (TMA). We demonstrate that PLA2G2A is an important marker of MIS-C that associates with TMA. We find that IFNγ responses are dysregulated in MIS-C patients, and that IFNγ levels delineate clinical heterogeneity.
Multi-inflammatory syndrome in children (MIS-C) can be associated with SARS-CoV-2 infection but can also be similar to other inflammatory syndromes. Here the authors characterise the plasma proteome phenotype in MIS-C and compare to other SARS-CoV-2 related syndromes and find disproportionately high IFN-γ responses in MIS-C patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Oldridge, Derek A 5 ; Canna, Scott W 6 ; Henrickson, Sarah E 7 ; McNerney, Kevin O 8 ; Balamuth Frances 9 ; Chakkapong, Burudpakdee 1 ; Lee, Jessica 1 ; Leng Tomas 8
; Farrel Alvin 2 ; Lambert, Michele P 10
; Sullivan, Kathleen E 11 ; John, Wherry E 4
; Teachey, David T 1
; Bassiri Hamid 12 ; Behrens, Edward M 6 1 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
2 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
3 University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
4 University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
5 University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Pathology and Laboratory Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
6 University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Rheumatology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
7 University of Pennsylvania Perelman School of Medicine, Division of Allergy and Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
8 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
9 University of Pennsylvania Perelman School of Medicine, Division of Emergency Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
10 University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
11 University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Allergy and Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
12 University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)




